27.72

0.32% -0.09

Pre-market: 27.34 -0.38 -1.37%

Harmony Biosciences Holdings Inc (HRMY)

Overview News Price History Option Chain Financials Why HRMY Down? Discussions Forecast

Harmony Biosciences Holdings Inc stock is traded at $27.72, with a volume of 1.03M. It is down -0.32% in the last 24 hours and down -4.94% over the past month. Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company has one reportable segment: rare neurological diseases. Its product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.

Previous Close:

$27.81

Open:

$27.9

24h Volume:

1.03M

Relative Volume:

1.23

Market Cap:

$1.60B

Revenue:

$868.45M

Net Income/Loss:

$158.69M

P/E Ratio:

10.23

EPS:

2.7087

Net Cash Flow:

$328.64M

1W Performance:

+0.40%

1M Performance:

-4.94%

6M Performance:

-14.81%

1Y Performance:

-20.57%

1-Day Range:

$27.51

$27.99

1-Week Range:

$27.11

$28.92

52-Week Range:

$25.52

$40.87

Harmony Biosciences Holdings Inc Stock (HRMY) Company Profile

Name

Harmony Biosciences Holdings Inc

Sector

Healthcare (1108)

Industry

Biotechnology (621)

Phone

(484) 539-9800

Address

630 W GERMANTOWN PIKE, PLYMOUTH MEETING

Employee

293

Twitter

Next Earnings Date

2024-10-29

Latest SEC Filings

HRMY's Discussions on Twitter

Compare HRMY vs VRTX, REGN, ALNY, ARGX, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
HRMY Harmony Biosciences Holdings Inc	27.72	1.60B	868.45M	158.69M	328.64M	2.7087
VRTX Vertex Pharmaceuticals Inc	454.00	115.33B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	732.87	77.48B	14.34B	4.50B	3.77B	41.56
ALNY Alnylam Pharmaceuticals Inc	312.17	41.40B	3.71B	313.75M	465.38M	2.2571
ARGX Argen X Se Adr	663.93	41.09B	4.16B	1.29B	734.26M	19.58
ONC Beone Medicines Ltd Adr	275.28	30.56B	5.36B	287.73M	924.18M	2.5229

Harmony Biosciences Holdings Inc Stock (HRMY) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Feb-23-26	Downgrade	Deutsche Bank	Buy → Hold
Feb-23-26	Downgrade	Truist	Buy → Hold
Feb-11-26	Resumed	UBS	Neutral
Jul-21-25	Initiated	Truist	Buy
Jul-10-25	Resumed	Goldman	Neutral
Jun-02-25	Resumed	Oppenheimer	Outperform
Feb-11-25	Initiated	Deutsche Bank	Buy
Dec-17-24	Initiated	H.C. Wainwright	Buy
Oct-10-24	Resumed	Raymond James	Outperform
Sep-10-24	Initiated	UBS	Buy
Jun-21-24	Initiated	Citigroup	Buy
Jan-02-24	Downgrade	BofA Securities	Neutral → Underperform
Sep-25-23	Downgrade	Goldman	Neutral → Sell
Sep-07-23	Initiated	Berenberg	Buy
Apr-20-23	Initiated	BofA Securities	Neutral
Oct-14-22	Upgrade	Janney	Neutral → Buy
Oct-14-22	Upgrade	Jefferies	Hold → Buy
Aug-03-22	Downgrade	Jefferies	Buy → Hold
Jul-13-22	Downgrade	Goldman	Buy → Neutral
Jul-07-22	Initiated	Mizuho	Buy
Apr-14-22	Initiated	Cantor Fitzgerald	Overweight
Dec-01-21	Initiated	Oppenheimer	Outperform
Nov-04-21	Initiated	Raymond James	Outperform
Sep-23-21	Initiated	Needham	Buy
Mar-29-21	Upgrade	Goldman	Neutral → Buy
Sep-14-20	Initiated	Goldman	Neutral
Sep-14-20	Initiated	Jefferies	Buy
Sep-14-20	Initiated	Piper Sandler	Overweight

View All

Harmony Biosciences Holdings Inc Stock (HRMY) Latest News

02:44 AM

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Receives Average Recommendation of "Hold" from Brokerages - MarketBeat

02:44 AM

Mar 21, 2026

Harmony Biosciences to report Q4 and full-year 2025 results - MSN

Mar 21, 2026

Mar 20, 2026

HRMY Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI

Mar 20, 2026

HRMY Earning Date, Earning Analysis and Earning Prediction - Intellectia AI

Mar 20, 2026

Are options traders betting on a big move in Harmony Biosciences stock? - MSN

Mar 20, 2026

Mar 19, 2026

Are Options Investors Anticipating Significant Volatility in Harmony Biosciences Shares? - Bitget

Mar 19, 2026

Are Options Traders Betting on a Big Move in Harmony Biosciences Stock? - TradingView

Mar 19, 2026

(HRMY) Movement as an Input in Quant Signal Sets - Stock Traders Daily

Mar 19, 2026

Bull Bear: Is Harmony Biosciences Holdings Inc impacted by rising ratesTrade Risk Report & Long-Term Investment Growth Plans - baoquankhu1.vn

Mar 19, 2026

Mar 18, 2026

Harmony Biosciences targets $1B–$1.04B WAKIX revenue in 2026 while expanding late-stage CNS pipeline - MSN

Mar 18, 2026

FOMO Trade: Can Harmony Biosciences Holdings Inc reach all time highs this year2026 Sector Review & Momentum Based Trading Signals - baoquankhu1.vn

Mar 18, 2026

Can Harmony Biosciences Holdings Inc reach all time highs this year - baoquankhu1.vn

Mar 18, 2026

Mar 17, 2026

Harmony Biosciences Stock Offers a Rare Buying Opportunity - Barron's

Mar 17, 2026

Aug Spikes: Whats the profit margin of Harmony Biosciences Holdings Inc2026 Technicals & Fast Gain Swing Alerts - baoquankhu1.vn

Mar 17, 2026

Mar 16, 2026

Harmony Biosciences reports 2025 revenue growth, issues 2026 outlook - MSN

Mar 16, 2026

Mar 14, 2026

Deutsche Bank cuts PT on Harmony Biosciences Holdings (HRMY) to $30 from $31 - MSN

Mar 14, 2026

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Short Interest Update - MarketBeat

Mar 14, 2026

Zuckerman Investment Group LLC Invests $3.40 Million in Harmony Biosciences Holdings, Inc. $HRMY - MarketBeat

Mar 14, 2026